🚀 VC round data is live in beta, check it out!
Chongqing Zhifei Valuation Multiples
Discover revenue and EBITDA valuation multiples for Chongqing Zhifei and similar public comparables like Sumitomo Pharma, Caliway Biopharmaceuticals, Shanghai RAAS, CRISPR Therapeutics and more.
Chongqing Zhifei Overview
About Chongqing Zhifei
Chongqing Zhifei Biological Products Co Ltd is engaged in research and development, production, and sales of vaccines and biological products. The company's main products include bacterial vaccines for the prevention of meningitis and pneumonia-based bacteria, biological products for the prevention and treatment of tuberculosis, viral vaccines for the prevention of rabies virus, influenza virus, and other viruses, general drugs and other biological products, among others.
Founded
2009
HQ
Employees
7.2K
Website
Sectors
Financials (LTM)
EV
$7B
Chongqing Zhifei Financials
Chongqing Zhifei reported last 12-month revenue of $2B and negative EBITDA of ($81M).
In the same LTM period, Chongqing Zhifei generated ($81M) in EBITDA losses and had net loss of ($1B).
Revenue (LTM)
Chongqing Zhifei P&L
In the most recent fiscal year, Chongqing Zhifei reported revenue of $4B and EBITDA of $416M.
Chongqing Zhifei expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $4B | XXX | XXX | XXX |
| Gross Profit | — | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | — | XXX | 27% | XXX | XXX | XXX |
| EBITDA | ($81M) | XXX | $416M | XXX | XXX | XXX |
| EBITDA Margin | (5%) | XXX | 11% | XXX | XXX | XXX |
| EBIT Margin | (10%) | XXX | 12% | XXX | XXX | XXX |
| Net Profit | ($1B) | XXX | $296M | XXX | XXX | XXX |
| Net Margin | (80%) | XXX | 8% | XXX | XXX | XXX |
| Net Debt | — | — | $1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Chongqing Zhifei Stock Performance
Chongqing Zhifei has current market cap of $5B, and enterprise value of $7B.
Market Cap Evolution
Chongqing Zhifei's stock price is $2.27.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7B | $5B | -1.4% | XXX | XXX | XXX | $0.12 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialChongqing Zhifei Valuation Multiples
Chongqing Zhifei trades at 4.5x EV/Revenue multiple, and (88.4x) EV/EBITDA.
EV / Revenue (LTM)
Chongqing Zhifei Financial Valuation Multiples
As of April 19, 2026, Chongqing Zhifei has market cap of $5B and EV of $7B.
Equity research analysts estimate Chongqing Zhifei's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Chongqing Zhifei has a P/E ratio of (4.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV/Revenue | 4.5x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | (88.4x) | XXX | 17.2x | XXX | XXX | XXX |
| EV/EBIT | (43.6x) | XXX | 16.1x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 6.8x | XXX | XXX | XXX |
| P/E | (4.3x) | XXX | 18.3x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (9.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Chongqing Zhifei Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Chongqing Zhifei Margins & Growth Rates
Chongqing Zhifei's revenue in the last 12 month grew by 2%.
Chongqing Zhifei's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.
Chongqing Zhifei's rule of 40 is 1% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Chongqing Zhifei's rule of X is 2% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Chongqing Zhifei Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | (59%) | XXX | XXX | XXX |
| EBITDA Margin | (5%) | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | (195%) | XXX | (129%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 1% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 2% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 16% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Chongqing Zhifei Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Chongqing Zhifei | XXX | XXX | XXX | XXX | XXX | XXX |
| Sumitomo Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Caliway Biopharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Shanghai RAAS | XXX | XXX | XXX | XXX | XXX | XXX |
| CRISPR Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Beijing Tongrentang | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chongqing Zhifei M&A Activity
Chongqing Zhifei acquired XXX companies to date.
Last acquisition by Chongqing Zhifei was on XXXXXXXX, XXXXX. Chongqing Zhifei acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Chongqing Zhifei
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialChongqing Zhifei Investment Activity
Chongqing Zhifei invested in XXX companies to date.
Chongqing Zhifei made its latest investment on XXXXXXXX, XXXXX. Chongqing Zhifei invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Chongqing Zhifei
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Chongqing Zhifei
| When was Chongqing Zhifei founded? | Chongqing Zhifei was founded in 2009. |
| Where is Chongqing Zhifei headquartered? | Chongqing Zhifei is headquartered in China. |
| How many employees does Chongqing Zhifei have? | As of today, Chongqing Zhifei has over 7K employees. |
| Who is the CEO of Chongqing Zhifei? | Chongqing Zhifei's CEO is Rensheng Jiang. |
| Is Chongqing Zhifei publicly listed? | Yes, Chongqing Zhifei is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Chongqing Zhifei? | Chongqing Zhifei trades under 300122 ticker. |
| When did Chongqing Zhifei go public? | Chongqing Zhifei went public in 2010. |
| Who are competitors of Chongqing Zhifei? | Chongqing Zhifei main competitors are Sumitomo Pharma, Caliway Biopharmaceuticals, Shanghai RAAS, CRISPR Therapeutics. |
| What is the current market cap of Chongqing Zhifei? | Chongqing Zhifei's current market cap is $5B. |
| What is the current revenue of Chongqing Zhifei? | Chongqing Zhifei's last 12 months revenue is $2B. |
| What is the current revenue growth of Chongqing Zhifei? | Chongqing Zhifei revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Chongqing Zhifei? | Current revenue multiple of Chongqing Zhifei is 4.5x. |
| Is Chongqing Zhifei profitable? | No, Chongqing Zhifei is not profitable. |
| What is the current EBITDA of Chongqing Zhifei? | Chongqing Zhifei has negative EBITDA and is not profitable. |
| What is Chongqing Zhifei's EBITDA margin? | Chongqing Zhifei's last 12 months EBITDA margin is (5%). |
| What is the current EV/EBITDA multiple of Chongqing Zhifei? | Current EBITDA multiple of Chongqing Zhifei is (88.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.